Epigallocatechin-3-gallate Attenuates Renal Damage by Suppressing Oxidative Stress in Diabetic db/db Mice

Table 2

Changes of 24-hour urinary protein, urinary 8-iso-PGF2a, and renal Ang II levels in urine 24 h after different treatment.

	Normal	Control	EGCG A	EGCG B
24-hour urinary protein (mg)
Baseline	1.2 ± 0.3	5.8 ± 0.6	5.9 ± 0.9	5.7 ± 1.1
Week 4	1.1 ± 0.7	7.5 ± 0.2	6.7 ± 0.1	6.7 ± 0.5
Week 8	1.3 ± 0.5	11.9 ± 1.3	8.8 ± 1.0	8.6 ± 1.1
Urinary 8-iso-PGF2a (ng/d)
Baseline	38.5 ± 5.3	84.6 ± 8.5	87.2 ± 11.3	86.8 ± 12.1
Week 4	39.8 ± 3.6	150.4 ± 11.9	107.3 ± 12.1	110.6 ± 9.2
Week 8	38.7 ± 4.4	176.8 ± 10.1	138.5 ± 8.3	126.7 ± 9.5
Renal Ang II (ng/L)
Baseline	177.6 ± 20.2	238.3 ± 14.2	240.5 ± 19.8	238.9 ± 16.6
Week 4	182.4 ± 12.1	346.2 ± 22.7	297.5 ± 15.5	308.9 ± 7.3
Week 8	191.3 ± 23.9	405.8 ± 7.2	367.4 ± 5.4	383.7 ± 9.6

Note: normal, C57BLKS/J normal nontreated mice; control, C57BLKS/J db/db nontreated mice; EGCG A, db/db mice treated with EGCG of 50 mg/kg/d; EGCG B, db/db mice treated with EGCG of 100 mg/kg/d; urinary 8-iso-PGF2a, urinary 8-iso-prostaglandin F2α; Ang II: the renal angiotensin II concentration; versus normal; and versus control; values are means ± SEM. At baseline and at week 4, in each group; at week 8, in each group.